Theranostics Subcommittee

THURSDAY, OCTOBER 8 • 6:15 – 7:15 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

6:00 - 6:05 pm	***Welcome***	Jeffrey Wong, MD Tanya Dorff, MD Jeremie Calais, MD, PhD
6:05 - 6:20 pm	***Update from IROC***	Michael Knopp, MD, PhD
6:25 – 6:45 pm	***Dosimetry-Guided ^{177}Lu-PSMA-617 Treatment for mCRPC***	Ravi Patel, MD, PhD
6:50 – 7:10 pm	***Phase 2 Randomized Trial of Lu177+SBRT vs. ARPI+Lu177+SBRT for mHSPC (virtual)***	Adeel Kaiser, MD
7:10 pm	***Future Speakers and Closing Remarks***	Jeffrey Wong, MD

November 6, 2026

Pentixapharm, Inc.
Radiolabeled CXCR4-targeting compounds, PentixaTher and PentixaFor- imaging and therapy of hematopoietic malignancies

Disease Sites of interest
Acute leukemia
BMT conditioning acute leukemia undergoing allo-HCT
Multiple Myeloma
Lymphoma

December 4, 2026

Pentixapharm, Inc.
GT-008 is a CD24-targeting mAb- theranostic agent in female cancers (breast, ovarian).

Disease Sites of Interest
Breast
Ovarian / GYN